ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Sunday, November 12, 2023

4:00PM-5:30PM: Abstract Number: 0800

CD4+ CD96+ T Cells Are Pathogenic Effector Cells in Giant Cell Arteritis

Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease

4:00PM-5:30PM: Abstract Number: 0857

Change in Albuminuria in Patients with ANCA-Associated Vasculitis Treated with Avacopan

Abstracts: Vasculitis – ANCA-Associated I

4:00PM-5:30PM: Abstract Number: 0834

Characterization of the Youngest Cohort with Non-Systemic Juvenile Idiopathic Arthritis: Demographics and Medication Use of Patients ≤2 Years of Age in the Childhood Arthritis and Rheumatology Research Alliance Registry

Abstracts: Pediatric Rheumatology – Clinical I: JIA

4:00PM-5:30PM: Abstract Number: 0811

Comparative Effectiveness of Sodium-glucose cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-primary Emergency Department Visits and Hospitalizations: A General Population Cohort Study

Abstracts: Metabolic & Crystal Arthropathies – Basic & Clinical Science

4:00PM-5:30PM: Abstract Number: 0817

Comparative Effectiveness of Yoga and Strengthening Exercise for Treating Knee OsteoArthritis: A Randomised Controlled Trial (YOGA Trial)

Abstracts: Osteoarthritis I: Clinical Trials

4:00PM-5:30PM: Abstract Number: 0832

Cumulative Social Disadvantage Is Associated with Disease Activity and Functional Disability in Juvenile Idiopathic Arthritis: An Analysis of the CARRA Registry

Abstracts: Pediatric Rheumatology – Clinical I: JIA

4:00PM-5:30PM: Abstract Number: 0805

De-escalation of Anti-TNFs in Older Adults with Rheumatoid Arthritis

Abstracts: Health Services Research I

4:00PM-5:30PM: Abstract Number: 0829

Decreased History of Breastfeeding During Infancy in Juvenile Spondyloarthritis: A Case-Control Study

Abstracts: Pediatric Rheumatology – Clinical I: JIA

4:00PM-5:30PM: Abstract Number: 0824

Defining Poor Global Functioning and Health in Axial Spondyloarthritis, Using the EQ-5D-3L Questionnaire, When the ASAS-Health Index Is Not Available Is Feasible. an Analysis of 2651 Patients from the PERSPA Study

Abstracts: Patient Outcomes, Preferences, & Attitudes I: Assessment Tools

4:00PM-5:30PM: Abstract Number: 0827

Development and Initial Validation of a Brief Measure of Uncertainty in Rheumatic Disease

Abstracts: Patient Outcomes, Preferences, & Attitudes I: Assessment Tools

4:00PM-5:30PM: Abstract Number: 0826

Development of a Decision Aid for Clinical Trial Participation in Systemic Lupus Erythematosus

Abstracts: Patient Outcomes, Preferences, & Attitudes I: Assessment Tools

4:00PM-5:30PM: Abstract Number: 0847

Development of an IFN 5-Gene Signature Score to Identify IFN-high and IFN-low Subsets and as a Pharmacodynamic Biomarker for Deucravacitinib Treatment in a Phase 2 Trial in Patients with Systemic Lupus Erythematosus

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes I: Biomarkers

4:00PM-5:30PM: Abstract Number: 0856

Dupilumab for Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study

Abstracts: Vasculitis – ANCA-Associated I

4:00PM-5:30PM: Abstract Number: 0853

Early Experience with Avacopan for ANCA-Associated Vasculitis in a Large Integrated Healthcare System

Abstracts: Vasculitis – ANCA-Associated I

4:00PM-5:30PM: Abstract Number: 0806

Effectiveness of a Technology-enabled Self-monitoring and Physical Therapist Counselling Program for Improving Self-management Ability in People with Rheumatoid Arthritis: A Randomized Controlled Trial

Abstracts: Health Services Research I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].